Republican lawmakers have filed a united appeal urging the Supreme Court to restore an in-person dispensing requirement for the abortion drug mifepristone, arguing that the current mail-and-telemedicine policy puts women at risk of coercion and serious medical harm. The amicus brief, led by Sen. Bill Cassidy, Rep. Chris Smith, John Thune and Speaker Mike Johnson, backs Louisiana’s challenge and points to alleged cases where pills were obtained or administered without consent. The dispute follows a Fifth Circuit ruling that reinstated the in-person rule and prompted emergency appeals from drug makers who say the decision is creating confusion. The outcome before the high court could determine whether mail-order access remains the norm or tighter safeguards return.
The brief’s core contention is that the Biden-era change to the FDA’s Risk Evaluation and Mitigation Strategy removed a crucial layer of protection and “increases the risk of coercion,” a direct phrase the filing uses to describe the effect of mail distribution. Lawmakers frame the in-person requirement not as an obstacle to care but as a safeguard against abuse, coercion and missed diagnoses. They argue that face-to-face medical oversight gives doctors the chance to verify consent and assess physical health in ways remote visits cannot.
The filing highlights several disturbing allegations, including the account of Rosalie Markezich, who says her boyfriend ordered mifepristone from a distant doctor and coerced her into taking it. The brief quotes the case directly: “Had she visited a doctor in person, her boyfriend would never have been able to obtain the drugs he made [her] take,” the brief says. That bracketed detail remains, and lawmakers say it illustrates how remote prescribing can be exploited by abusers to force a medical outcome.
Other examples cited in the filing include a Louisiana mother who allegedly obtained pills online for her teenage daughter, which reportedly led to a medical emergency, and a separate allegation of a man administering abortion pills without a woman’s knowledge. Republican backers say these incidents are not hypothetical and that the pattern of remote access plus shipping increases the chance of harm. They stress that in-person assessment can help spot signs of coercion, underage involvement and conditions like ectopic pregnancy that require urgent care.
Sen. Cassidy has urged a quick return to prior safeguards, arguing the change was reckless and put mothers and children at risk. He told the court plainly, “Chemical abortion drugs kill innocent children and put mothers’ lives at risk,” Cassidy said. That language underscores the Republican stance that safety and protection should take precedence over expanded access when the expansion removes vital oversight.
The legal posture intensified when mifepristone manufacturers Danco Laboratories and GenBioPro filed emergency appeals asking the Supreme Court to pause the Fifth Circuit’s order. The companies warn that reinstating the in-person rule nationwide would cause “immediate confusion and upheaval” for providers, pharmacies and patients who have relied on mail-order systems. Lawmakers counter that regulatory convenience cannot outweigh documented harms and the basic duty to prevent abuse.
Republicans in the brief also press a statutory angle, asserting the FDA exceeded its authority by allowing mailed distribution that, they say, conflicts with federal statutes like the Comstock Act. They contend the agency used limited safety data to justify removing the in-person requirement and weakened adverse-event reporting standards in the process. That, the brief argues, left the public with fewer protections at the exact moment the risk of misuse grew.
Beyond statutory and procedural claims, the filing stresses practical medical concerns: remote prescribing makes it harder for clinicians to detect ectopic pregnancies and other serious conditions, and it hampers the ability to identify coercion or abuse. Republican signers say restoring face-to-face dispensing would not ban care but would reintroduce a commonsense checkpoint for safety. They want the court to preserve established guardrails while health authorities take the time to reassess safety data.
The Supreme Court is now considering emergency requests from the manufacturers to block the Fifth Circuit’s order while the litigation continues, setting up a high-stakes decision with nationwide consequences. Lawmakers like Leader Thune have been blunt in their appeal: “There are legitimate concerns about these drugs putting women and girls at significant risk,” said Leader Thune. The case invites the justices to decide whether convenience and expanded access trump protections against coercion and medical danger.
Darnell Thompkins is a conservative opinion writer from Atlanta, GA, known for his insightful commentary on politics, culture, and community issues. With a passion for championing traditional values and personal responsibility, Darnell brings a thoughtful Southern perspective to the national conversation. His writing aims to inspire meaningful dialogue and advocate for policies that strengthen families and empower individuals.